Clinical trial

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

NCT01981473

Study summary

ClinicalTrials.gov

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

OTHER · Unmapped registry intervention no intervention Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2014-01-01

PhaseN/A

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

no interventionOTHER

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

HoustonTexas, United States2 PhoenixArizona, United States2 BaltimoreMaryland, United States1 TampaFlorida, United States1 AustinTexas, United States1 CharlotteNorth Carolina, United States1 SacramentoCalifornia, United States1 GainesvilleFlorida, United States1 SofiaBulgaria1 Fort LauderdaleFlorida, United States1 SpokaneWashington, United States1 AnkaraTurkey (Türkiye)1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01981473 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.